NCT03370835

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

Randomized Open-Label Crossover Trial Comparing Tolerability of a Cardioselective Beta-Blocker (Metoprolol-Succinate-ER) and a Non-Cardioselective Beta-Blocker (Carvedilol) in Patients With Chronic Obstructive Pulmonary Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: VA Greater Los Angeles Healthcare System · Federal
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Use of beta-blockers has proven beneficial in patients with hypertension, heart failure, and in people who have suffered a heart attack. The use in patients who have Chronic Obstructive Pulmonary Disease (COPD) and reactive airway disease, however, has been limited due to possible side effects such as worsening of lung function or increasing airway spasms and asthma attacks. The purpose of this study is to find out if patients with COPD can tolerate being on a beta-blocker at doses recommended for the treatment of heart disease conditions. This study also seeks to find out if a selective beta-1 receptor beta-blocker is better than a non-selective beta-blocker in patients with mild to moderate COPD.

Conditions

• Pulmonary Disease, Chronic Obstructive
• Asthma
• Adverse Effect of Beta-adrenoreceptor Antagonists

Interventions

Type	Name	Description
DRUG	Metoprolol succinate ER	Cardioselective beta-blocker
DRUG	Carvedilol	Non-cardioselective beta-blocker

Timeline

• Start date: 2004-06-01
• Primary completion: 2008-06-01
• Completion: 2008-06-01
• First posted: 2017-12-12
• Last updated: 2017-12-12

Locations

1 site across 1 country: United States